Yes, Emend Treats Chemo-Induced Nausea
Emend (fosaprepitant dimeglumine or aprepitant) is an FDA-approved antiemetic specifically for preventing acute and delayed nausea and vomiting caused by chemotherapy, especially highly emetogenic regimens like cisplatin-based treatments.[1] It's given as an IV injection on day 1 of chemo, often with oral aprepitant on days 2-3, combined with dexamethasone and a 5-HT3 antagonist like ondansetron.[2]
How Emend Works During Chemo
Emend blocks substance P/neurokinin 1 (NK1) receptors in the brain's vomiting center, targeting delayed nausea that other drugs miss. Clinical trials showed it reduces complete response rates (no vomiting, no rescue meds) to 71% vs. 52% with standard therapy alone in highly emetogenic chemo.[3]
Common Chemo Regimens Using Emend
Primarily for moderate-to-highly emetogenic chemo:
- Cisplatin ≥50 mg/m²
- Anthracyclines + cyclophosphamide (e.g., breast cancer regimens)
- Carboplatin-based therapies
Guidelines from ASCO, NCCN, and MASCC recommend it as first-line for these.[4]
Who Gets Emend for Chemo and Dosing
Adult patients starting initial or repeat chemo cycles. Standard regimen:
- Day 1: 150 mg IV (fosaprepitant) 30 min before chemo
- Days 2-3: 80 mg oral aprepitant daily
Pediatric use approved for ages 6 months+ in similar settings.[1]
Emend vs. Other Anti-Nausea Drugs for Chemo
| Drug | Target | Best For | Key Difference from Emend |
|-----|--------|----------|---------------------------|
| Ondansetron (Zofran) | 5-HT3 receptors | Acute nausea | Misses delayed phase; Emend adds NK1 coverage |
| Dexamethasone | Corticosteroid | Both phases | Broad but shorter-term; pairs with Emend |
| Rolapitant (Varubi) | NK1 like Emend | Delayed nausea | Single-dose oral; no CYP3A4 interaction issues |
| Netupitant/palonosetron (Akynzeo) | NK1 + 5-HT3 | Combo acute/delayed | Oral fixed combo; Emend has IV option |
Emend outperforms placebo and matches rolapitant in trials but interacts with CYP3A4 drugs (e.g., avoid with strong inhibitors like ketoconazole).[2]
Side Effects Patients Report with Chemo Use
Most common: fatigue (26%), diarrhea (19%), constipation (18%), hiccups (12%). Serious risks include hypersensitivity (IV form) and neutropenia. No QT prolongation unlike some 5-HT3 drugs.[1] Patient forums note less "chemo hangover" nausea vs. alternatives.
Cost and Access for Chemo Patients
IV Emend ~$600-800 per dose (U.S., uninsured); generics available since 2023 lower costs. Covered by most insurance for indicated chemo; patient assistance via Merck.[5]
Patent Status and Generic Availability
Original patents expired; fosaprepitant generics from Hikma, Sandoz launched 2023. Aprepitant oral generics since 2009. Check DrugPatentWatch.com for litigation updates—no major exclusivity blocks remain.6
[1]: FDA Label - Emend (merck.com)
[2]: NCCN Guidelines - Antiemesis (nccn.org)
[3]: NEJM 2005; Hesketh et al. trial
[4]: ASCO 2020 Antiemetic Guidelines
[5]: GoodRx pricing data